Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia.

@article{Knechtli1998MinimalRD,
  title={Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia.},
  author={C J Knechtli and Nick Goulden and John P. Hancock and Victoria L Grandage and E. L. Harris and Rhonda J Garland and Carl G. Jones and Anthony W Rowbottom and Linda P. Hunt and Aaron Green and Ed Clarke and Arjan Lankester and Jaqueline M Cornish and Derwood H Pamphilon and Colin Graham Steward and Anthony H Oakhill},
  journal={Blood},
  year={1998},
  volume={92 11},
  pages={4072-9}
}
The efficacy of allografting in acute lymphoblastic leukemia (ALL) is heavily influenced by remission status at the time of transplant. Using polymerase chain reaction (PCR)-based minimal residual disease (MRD) analysis, we have investigated retrospectively the impact of submicroscopic leukemia on outcome in 64 patients receiving allogeneic bone marrow transplantation (BMT) for childhood ALL. Remission BM specimens were taken 6 to 81 days (median, 23) before transplant. All patients received… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 91 extracted citations

Treating refractory leukemias in childhood, role of clofarabine

Therapeutics and clinical risk management • 2008
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1998

Similar Papers

Loading similar papers…